Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities)
Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities)
Commack, New York, United States3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, hairy cell leukemia, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-08-24 | NCT03410875 | |
| Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer | Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, thyroid gland undifferentiated (anaplastic) carcinoma | Active, not recruiting | Early phase 1 | 2026-07-07 | NCT03085056 | |
| Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, thyroid gland disorder, thyroid gland undifferentiated (anaplastic) carcinoma, thyroid tumor | Active, not recruiting | Phase 2 | 2026-07-06 | NCT04238624 |